Inhibition of Metformin combined with Gefitinib on EGFR-TKI Primary Resistant Non-small Cell Lung Cancer
This article explores the inhibitory effect of gefitinib combined with metformin on lung cancer H1975 cells and its mechanism. MTT and clone formation experiments were used to observe the effects of gefitinib and metformin alone or in combination on the proliferation of primary drug-resistant non-small cell lung cancer H1975 cells.The results showed that the inhibitory effect of methotrexate combined with metformin on proliferation, invasion and migration of H1975 cells was better than that of the control group, and the synergistic effect was significant (P<0.05). The apoptosis of gefitinib and metformin alone was lower than that of the control group. The rate increased, and the apoptotic rate increased more significantly when the two were combined (P<0.05), and the anti-apoptosis-related proteins (Bcl-xl, Mcl-1) and the pro-apoptotic protein Bax were up-regulated. The expression level of related proteins is decreased, and the expression level of epithelial cell-associated protein E-cadherin is increased.Conclusion: Gefitinib combined with metformin can significantly inhibit the proliferation, invasion and migration of EGFR-TKIs primary non-small cell lung cancer H1975 cells, and promote tumor cell apoptosis. The mechanism may be through activation of mitochondrial apoptosis pathway and reversal of EMT. It occurs to exert an anti-tumor effect.